Bioconjugate & ADC Formulation Development

Tailored formulation development for your product.

Robust formulations tailored to your needs.

Customized for your bioconjugate or antibody drug conjugate (ADC) development phase, Abzena will align your drug to your preferred target product profile (TPP) with a comprehensive range of formulation development packages including stable liquid and lyophilized formulations.

Contact Us

We select your best lead candidate through screening of optimal buffer conditions and formulation options to inform successful drug substance manufacturing conditions and drug product forms that support long-term stability.

Our team is experienced in developing formulations for small and large therapeutic molecules such as peptides, proteins, monoclonal antibodies and antibody-drug conjugates (ADCs).

Our Capabilities

We have the latest analytical equipment and methods to evaluate the integrity of your drug under an array of conditions to inform optimal formulation constituents and forms.

Our capabilities include:

  • UHPLC systems
  • Biophysical stability assessment platforms and particle size assessment equipment such as Prometheus, UNcle and ZetaSizer Ultra
  • Mass spectrometry instruments (TOF MS, QTOF MS)
  • Microfluidic platform (LabChip)

Let’s move medicine forward

The treatments you’re developing right now can make a real difference for human health. We can work together to ensure your success, combining our deep scientific and technical know-how with your promising asset.